12:00 AM
 | 
Jul 22, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

NBI-98854: Completed Phase IIb enrollment

Neurocrine completed enrollment of 120 patients with moderate to severe tardive dyskinesia and underlying schizophrenia or schizoaffective disorder in the double-blind, U.S. Phase IIb Kinect Study evaluating once-daily, oral NBI-98854 for 6 weeks. Patients will receive 50 mg NBI-98854 for 6 weeks; 100 mg NBI-98854 for...

Read the full 209 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >